Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,963
  • Shares Outstanding, K 74,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,020 K
  • 36-Month Beta 2.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.16
  • Low Estimate -0.19
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +5.41%
on 08/13/18
3.03 -35.64%
on 07/19/18
-0.89 (-31.34%)
since 07/13/18
3-Month
1.85 +5.41%
on 08/13/18
3.70 -47.30%
on 06/20/18
-0.42 (-17.72%)
since 05/14/18
52-Week
1.41 +38.30%
on 08/15/17
4.09 -52.32%
on 12/27/17
+0.37 (+23.42%)
since 08/14/17

Most Recent Stories

More News
Sierra Oncology Reports Second Quarter Results

SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and prioritized...

SRRA : 1.95 (-4.88%)
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

- Presentation scheduled for 9:10 a.m. ET on August 15, 2018 -

SRRA : 1.95 (-4.88%)
ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

SRRA : 1.95 (-4.88%)
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

SRNE : 5.10 (-4.67%)
ONCE : 61.35 (+4.87%)
SRRA : 1.95 (-4.88%)
Bladder Cancer: Pipeline Review, H1 2018 - Key Company Analysis, Drug Profiles, and Opportunities - ResearchAndMarkets.com

The "Bladder Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. Bladder Cancer - Pipeline Review, H1 2018, provides comprehensive information...

BAYRY : 23.7700 (+0.78%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
SRRA : 1.95 (-4.88%)
ALPMF : 16.3600 (-2.33%)
NVS : 82.14 (-0.36%)
ADAP : 8.43 (-2.32%)
AMGN : 195.76 (+0.08%)
CELGZ : 1.70 (-0.58%)
PFE : 40.71 (-0.25%)
BMY : 59.96 (+0.91%)
FSCGF : 5.3000 (unch)
AZN : 38.98 (-0.10%)
AAVXF : 7.0000 (-2.10%)
LLY : 102.44 (unch)
SGEN : 74.63 (+1.12%)
ESALF : 85.0000 (-2.86%)
GSK : 39.80 (+0.08%)
BVNKF : 29.2500 (+1.92%)
MKKGY : 20.4700 (+0.61%)
OPHLF : 23.1500 (-10.65%)
Can The Uptrend Continue for Sierra Oncology (SRRA)?

Investors certainly have to be happy with Sierra Oncology, Inc. (SRRA) and its short term performance

SRRA : 1.95 (-4.88%)
Sierra Oncology to Present at the Jefferies Global Healthcare Conference in New York

Presentation scheduled for 8:30 a.m. ET on June 7, 2018 -

SRRA : 1.95 (-4.88%)
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

SRNE : 5.10 (-4.67%)
ONCE : 61.35 (+4.87%)
SRRA : 1.95 (-4.88%)
Sierra Oncology Reports First Quarter Results

SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - - $133.8 million...

SRRA : 1.95 (-4.88%)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

SRRA : 1.95 (-4.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SRRA with:

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 2.21
1st Resistance Point 2.08
Last Price 1.95
1st Support Level 1.88
2nd Support Level 1.81

See More

52-Week High 4.09
Fibonacci 61.8% 3.07
Fibonacci 50% 2.75
Fibonacci 38.2% 2.43
Last Price 1.95
52-Week Low 1.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar